{"id":"aripiprazole-or-perphenazine","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Akathisia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-15","effect":"Weight gain"},{"rate":"10-20","effect":"Extrapyramidal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole's partial agonist activity at dopamine receptors provides stabilization of dopaminergic signaling, reducing both excessive and insufficient dopamine activity. Perphenazine acts as a dopamine antagonist to reduce psychotic symptoms. Both drugs are used in psychiatric conditions where dopaminergic dysregulation contributes to symptomatology.","oneSentence":"Aripiprazole is a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist that modulates dopaminergic and serotonergic neurotransmission; perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:03.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment with aripiprazole)"},{"name":"Irritability associated with autism spectrum disorder (aripiprazole)"}]},"trialDetails":[{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT01193166","phase":"PHASE4","title":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","status":"WITHDRAWN","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00802100","phase":"PHASE4","title":"Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-12","conditions":"Schizophrenia","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7500,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abilify, Trilafon"],"phase":"marketed","status":"active","brandName":"Aripiprazole or Perphenazine","genericName":"Aripiprazole or Perphenazine","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist that modulates dopaminergic and serotonergic neurotransmission; perphenazine is a typical antipsychotic that blocks dopamine D2 receptors. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment with aripiprazole).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}